Trans-splicing, more than meets the eye: Multifaceted therapeutics for spinal muscular atrophy

Human Gene Therapy

Volumn 22, Issue 2, 2011, Pages 121-125

  Butchbach, Matthew E R ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; LENTIVIRUS VECTOR; NEUROTROPHIN; SOMATOMEDIN C; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TRICHOSTATIN A; VORINOSTAT;

DISEASE SEVERITY; DRUG MECHANISM; EXON; GENE DOSAGE; GENE DUPLICATION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; INTRON; NONHUMAN; NOTE; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL MUSCULAR ATROPHY; SURVIVAL RATE; TRANS SPLICING; TRANSGENE;

ANIMALS; GENE EXPRESSION; GENE THERAPY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, TRANSGENIC; MUSCULAR ATROPHY, SPINAL; SURVIVAL OF MOTOR NEURON 1 PROTEIN; SURVIVAL OF MOTOR NEURON 2 PROTEIN; TRANS-SPLICING;

EID: 79951826868     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2011.903     Document Type: Note

References (50)

1. Avila, A.M., Burnett, B.G., Taye, A.A., et al. (2007). Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117, 659-671. (Pubitemid 46348524)
2. Azzouz, M., Le, T., Ralph, G.S., et al. (2004). Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J. Clin. Invest. 114, 1726-1731. (Pubitemid 40385528)
3. Baughan, T., Shababi, M., Coady, T.H., et al. (2006). Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol. Ther. 14, 54-62. (Pubitemid 43899482)
4. Baughan, T.D., Dickson, A., Osman, E.Y., et al. (2009). Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum. Mol. Genet. 18, 1600-1611.
5. Burghes, A.H.M., and Beattie, C.E. (2009). Spinal muscular atrophy: Why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10, 597-609.
6. Butchbach, M.E.R., and Burghes, A.H.M. (2004). Perspectives on models of spinal muscular atrophy for drug discovery. Drug Disc. Today Dis. Models 1, 151-156. (Pubitemid 41123765)
7. Butchbach, M.E.R., Singh, J., Thorsteindóttir, M., et al. (2010). Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum. Mol. Genet. 19, 454-467.
8. Coady, T.H., and Lorson, C.L. (2010). Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J. Neurosci. 30, 126-130.
9. Coady, T.H., Shababi, M., Tullis, G.E., et al. (2007). Restoration of SMN function: Delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol. Ther. 15, 1471-1478. (Pubitemid 47099304)
10. Coady, T.H., Baughan, T.D., Shababi, M., et al. (2008). Development of single vector system that enhances trans-splicing of SMN2 transcripts. PLoS One 3, e3468.
11. Coovert, D.D., Le, T.T., McAndrew, P.E., et al. (1997). The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. 6, 1205-1214. (Pubitemid 27351059)
12. Crawford, T.O., and Pardo, C.A. (1996). The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 3, 97-110. (Pubitemid 26275339)
13. De Vry, J., Mart́nez-Mart́nez, P., Losen, M., et al. (2010). In vivo electroporation of the central nervous system: A non-viral approach for targeted gene delivery. Prog. Neurobiol. 92, 227-244.
14. Dickson, A., Osman, E., and Lorson, C.L. (2008). A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum. Gene Ther. 19, 1307-1315.
15. Dominguez, E., Marais, T., Chatauret, N., et al. (2011). Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20, 681-693.
16. Foust, K.D., Wang, X., McGovern, V.L., et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271-274.
17. Gavrilina, T.O., McGovern, V.L., Workman, E., et al. (2008). Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle specific SMN expression has no phenotypic effect. Hum. Mol. Genet. 17, 1063-1075. (Pubitemid 351494180)
18. Hastings, M.L., Berniac, J., Liu, Y.H., et al. (2009). Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci. Transl. Med. 1, 5-12.
19. Herweijer, H., and Wolff, J.A. (2007). Gene therapy progress and prospects: Hydrodynamic gene delivery. Gene Ther. 14, 99-107. (Pubitemid 46043816)
20. Hsieh-Li, H.M., Chang, J.G., Jong, Y.J., et al. (2000). A mouse model for spinal muscular atrophy. Nat. Genet. 24, 66-70. (Pubitemid 30041423)
21. Hua, Y., Vickers, T.A., Okunola, H.L., et al. (2008). Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 82, 834-848.
22. Hua, Y., Sahashi, K., Hung, G., et al. (2010). Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24, 1634-1644.
23. Jarecki, J., Chen, X., Bernardino, A., et al. (2005). Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: Early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. 14, 2003-2018. (Pubitemid 41418036)
24. Kaspar, B.K., Lladó, J., Sherkat, N., et al. (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839-842. (Pubitemid 36962626)
25. Le, T.T., Pham, L.T., Butchbach, M.E.R., et al. (2005). SMND7, the major product of the centromeric survival motor neuron gene (SMN2), extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845-857. (Pubitemid 40403280)
26. Lefebvre, S., Bü rglen, L., Reboullet, S., et al. (1995). Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155-165.
27. Lefebvre, S., Burlet, P., Liu, Q., et al. (1997). Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265-269. (Pubitemid 27280210)
28. G93A model of ALS. Brain Res. 1185, 256-265. (Pubitemid 350166301)
29. Lorson, C.L., Hahnen, E., Androphy, E.J., et al. (1999). A single nucleotide in the SMN gene regulates splicing an is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U.S.A. 96, 6307-6311. (Pubitemid 29256661)
30. Marquis, J., Meyer, K., Angehrn, L., et al. (2007). Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol. Ther. 15,1479-1486. (Pubitemid 47099305)
31. C gene copy number. Am. J. Hum. Genet. 60, 1411-1422. (Pubitemid 27258073)
32. Meyer, K., Marquis, J., Trü b, J., et al. (2009). Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum. Mol. Genet. 18, 546-555.
33. Michaud, M., Arnoux, T., Bielli, S., et al. (2010). Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. Neurobiol. Dis. 38, 125-135.
34. Monani, U.R., Lorson, C.L., Parsons, D.W., et al. (1999). A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 8, 1177-1183. (Pubitemid 29328985)
35. -/- mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333-339. (Pubitemid 30098725)
36. Monani, U.R., Pastore, M.T., Gavrilina, T.O., et al. (2003). A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J. Cell Biol. 160, 41-52. (Pubitemid 36091715)
37. Narver, H.L., Kong, L., Burnett, B.G., et al. (2008). Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann. Neurol. 64, 465-470.
38. Passini, M.A., Bu, J., Roskelley, E.M., et al. (2010). CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest. 120, 1253-1264.
39. Pathak, A., Patnaik, S., and Gupta, K.C. (2009). Recent trends in non-viral vector-mediated gene delivery. Biotechnol. J. 4, 1559-1572.
40. Riessland, M., Ackermann, B., Förster, A., et al. (2010). SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet. 19, 1492-1506.
41. Schrank, B., Götz, R., Gunnersen, J.M., et al. (1997). Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl. Acad. Sci. U.S.A. 94, 9920-9925. (Pubitemid 27408166)
42. Shababi, M., Glascock, J., and Lorson, C.L. (2011). Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum. Gene Ther. 22, 135-144.
43. Singh, N.K., Singh, N.N., Androphy, E.J., et al. (2006). Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26, 1333-1346. (Pubitemid 43202560)
44. Skordis, L., Dunckley, M.G., Yue, B., et al. (2003). Bifunc-tional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 100, 4114-4119. (Pubitemid 36418166)
45. Thurmond, J., Butchbach, M.E.R., Palomo, M., et al. (2008). Synthesis and biological evaluation of novel 2,4-diaminoqui-nazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J. Med. Chem. 51, 449-469. (Pubitemid 351252274)
46. Valori, C.F., Ning, K., Wyles, M., et al. (2010). Systemic delivery of scAAV9 expressin SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2, 35-42.
47. Viola, J.R., El-Andaloussi, S., Oprea, I.I., et al. (2010). Non-viral nanovectors for gene delivery: Factors that govern successful therapeutics. Expert Opin. Drug Deliv. 7, 721-735.
48. Williams, J.H., Schray, R.C., Patterson, C.A., et al. (2009). Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci. 29, 7633-7638.
49. Wood, M., Yin, H., and McClorey, G. (2007). Modulating the expression of disease genes with RNA-based therapy. PLoS Genet. 3, e109.
50. Workman, E., Saieva, L., Carrel, T.L., et al. (2009). A SMN mis-sense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. Hum. Mol. Genet. 18, 2215-2229.